Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2021 | CHRONOS-3: copanlisib plus rituximab for relapsed iNHL

Matthew Matasar • 12 Apr 2021
AACR 2021
Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia Antibodies Copanlisib Rituximab
CHRONOS-3

Matthew Matasar, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, shares an update on the randomized Phase III CHRONOS-3 trial (NCT02367040) of copanlisib plus rituximab versus rituximab and placebo in patients with relapsed indolent non-Hodgkin lymphoma (iNHL). At a median follow-up of 19.2 months, copanlisib plus rituximab demonstrated superior efficacy compared to placebo plus rituximab in patients with relapsed iNHL, with a median progression-free survival (PFS) of 21.5 months versus 13.8 months. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

Disclosures

Matthew Matasar, MD, has received support and honoraria from Bayer and Roche.

More from Matthew Matasar

0:55
Future treatment of relapsed iNHL
Matthew Matasar • 12 Apr 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals